Effects of nifedipine on baroreflex modulation of vascular resistance in man

American Heart Journal
|January 1, 1985
PubMed

Insights

Nifedipine, a calcium channel blocker, was studied in humans and found to alter baroreflex control of vascular resistance. This medication reduced vasoconstrictor responses to cold stimuli and norepinephrine, impacting blood pressure regulation.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Calcium channel blockers (CCBs) exhibit vascular effects and influence baroreceptor function.
  • Clinical doses of nifedipine's impact on human baroreflex control of vascular resistance require investigation.

Purpose of the Study:

  • To determine if clinically relevant doses of nifedipine alter baroreflex control of vascular resistance in normal humans.

Main Methods:

  • 14 healthy subjects underwent experiments assessing forearm vasoconstrictor responses.
  • Responses were measured during lower body negative pressure, cold pressor tests, and norepinephrine infusions.
  • Measurements were taken both before and after nifedipine administration.

Main Results:

  • Nifedipine increased heart rate and forearm blood flow, tending to decrease forearm vascular resistance.
  • Nifedipine significantly attenuated vasoconstrictor responses to cold pressor stimuli.
  • Nifedipine also depressed vasoconstrictor responses to intra-arterial norepinephrine infusion.

Conclusions:

  • Nifedipine affects baroreflex control of vascular resistance in humans.
  • The drug impairs the body's ability to constrict blood vessels in response to certain stimuli.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...